Table 4.
Association between each criterion of benzodiazepine misuse and adverse events among benzodiazepine users (final multivariate regression models) a
| Too long treatment (n = 105) | Concomitant treatment (n = 428) | Excessive dosage (n = 428) | ||||
|---|---|---|---|---|---|---|
| aOR | 95%CI | aOR | 95%CI | aOR | 95%CI | |
| Agitation | 7.88 | 1.63–38.12 | 2.05 | 0.84–4.98 | 1.58 | 0.63–3.96 |
| Neurological symptoms | 0.63 | 0.12–3.20 | 0.90 | 0.19–4.21 | 0.70 | 0.18–2.66 |
| Insomnia | 1.23 | 0.43–3.52 | 1.13 | 0.49–2.63 | 2.18 | 1.00–4.73 |
| Psychotic symptoms | 1.39 | 0.48–4.06 | 2.58 | 1.16–5.75 | 1.07 | 0.40–2.87 |
| Suicidal thoughts | 11.24 | 1.01–125.08 | 2.25 | 0.73–6.99 | 2.95 | 0.89–9.75 |
a
Full results of analysis are available in supplementary file.
aOR: odds ratio adjusted for age, sex and psychotropic coprescriptions (i.e. antidepressants, antipsychotics, mood stabilisers, drugs used to treat addiction and other sedatives).